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Background: Heparanase is involved in the pathology of many diseases.
Results: Heparanase cleaves heparan sulfate (HS) oligosaccharides in either consecutive or gapped cleavage mode.
Conclusion: The susceptibility of glycosidic linkage bonds to heparanase degradation is sensitive to the nonreducing end
saccharide structure of the cleavage site.
Significance: The results will help us to understand the pathophysiological effects of HS that arise from heparanase activity.
Heparan sulfate (HS) is a highly sulfated polysaccharide that
serves many biological functions, including regulating cell
growth and inflammatory responses as well as the blood coagu-
lation process. Heparanase is an enzyme that cleaves HS and is
known to display a variety of pathophysiological effects in can-
cer, diabetes, and Alzheimer disease. The link between hepara-
nase and diseases is a result of its selective cleavage of HS, which
releases smaller HS fragments to enhance cell proliferation,
migration, and invasion. Despite its importance in pathological
diseases, the structural cues in HS that direct heparanase cleav-
age and the steps of HS depolymerization remain unknown.
Here, we sought to probe the substrate specificity of heparanase
using a series of structurally defined oligosaccharide substrates.
The sites of heparanase cleavage on the oligosaccharide sub-
strates were determined by mass spectrometry and gel perme-
ation chromatography. We discovered that heparanase cleaves
the linkage of glucuronic acid linked to glucosamine carrying
6-O-sulfo groups. Furthermore, our findings suggest that hepa-
ranase displays different cleavage modes by recognizing the
structures of the nonreducing ends of the substrates.Our results
deepen the understanding of the action mode of heparanase.
Heparan sulfate (HS)3 is a structurally complex polysaccha-
ride that is expressed ubiquitously on the cell surface and in the
extracellular matrix. HS is composed of repeating disaccharide
units of glucuronic acid (GlcUA) and glucosamine. The gluco-
samine residues can bemodified byN-deacetylation andN- and
O-sulfations, and the GlcUA residues can undergo isomeriza-
tion to form iduronic acid (IdoUA) residues. Furthermore, the
2-OH position of GlcUA and IdoUA can be sulfated. The
unique sulfation patterns of HS and the presence of IdoUA
residues are believed to give rise to the selectivity that allowsHS
to exhibit different functions (1). The HS isolated from natural
tissues and cells consists of domains with different levels of
sulfations and epimerization (2). This domain-like structural
feature gives rise to segments that are highly sulfated, low sul-
fated, and unsulfated, respectively. Among these domains, the
highly sulfated domain interacts with various proteins contrib-
uting to their biological activity. In some cases, the protein
ligand binds to a specific arrangement of sulfated residues, and
in others, the interaction is primarily electrostatic. In either
case, the formation of these highly sulfated domains will deter-
mine whether a protein ligand binds to HS (3). Therefore, the
biosynthesis and the degradation process to release highly sul-
fated domains are likely to be tightly regulated to maintain the
physiological functions of HS. The current experimental evi-
dence suggests that the domain structures of HS are controlled
by HS biosynthetic enzymes, i.e. HS sulfotransferases (4), as
well as heparanase, which is a HS-degrading enzyme (5).
Heparanase is a glucuronidase that cleaves HS in a variety of
mammalian cells and tissues. It hydrolyzes the glycosidic bonds
between GlcUA and glucosamine residues that are located in
the low sulfated domain of HS (6). The action of heparanase
modulates the functions of HS to bind to a multitude of pro-
teins, including growth factors and their receptors, chemo-
kines, enzymes, and extracellular matrix proteins. In fact,
uncleaved HS lacks the ability to form a complex with protein
effector that is needed to induce signaling activity (7). For
example, basic fibroblast growth factor has been shown to be
sequestered by HS on the cell surface (8). However, heparanase
expressed by metastatic tumor cells and activated cells of the
immune system may release fibroblast growth factor, eliciting
an indirect neovascular response (9). Thus, heparanase acts as a
regulatory switch mediating the release of specifically tailored
saccharide structures within HS with restricted binding speci-
ficities. However, the substrate specificity and the mode of
action of heparanase remain unknown.
The actions of heparanase have been linked to numerous
human diseases, such as cancer, diabetes, and Alzheimer dis-
ease (10). Despite the biological significance of heparanase, less
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effort has been made to understand how structural cues within
HS structure may direct cleavage or the sequence of events
during HS depolymerization by heparanase. This is largely
because structurally heterogeneous polysaccharides were used
in the previous investigations (6). Only limited studies have
been carried out using structurally defined oligosaccharide sub-
strates or polysaccharides with simplified sulfation patterns
(11, 12). To date, it has been difficult to unambiguously assign
the mode of action of heparanase. Recently, we reported an
advanced chemoenzymatic method to synthesize HS oligosac-
charides with high efficiency and purity (13, 14). This method
allowed us to prepare structurally defined oligosaccharide sub-
strates to probe heparanase. Coupling the structurally defined
substrates withmass spectrometry analysis should improve the
accuracy of the substrate specificity of heparanase studies.
In this work, we probed the substrate specificity of hepara-
nase using a library of structurally defined oligosaccharides
ranging frompenta- to nonasaccharides. The products of hepa-
ranase cleavage were identified by electrospray ionization
(ESI)-MS to determine heparanase preference for endolytic or
exolytic cleavage at the reducing or nonreducing ends of sub-
strates. Furthermore, time course studieswere utilized to inves-
tigate whether heparanase cleaves distributively or processively
and the enzyme’s preference for certain substrates. Our data
suggest that heparanase utilizes key structural features within
HS to cleave endolytically toward the nonreducing end first.
Thus, the residue at the nonreducing end directs heparanase to
preserve or degrade the structure.Moreover, heparanase depo-
lymerizes HS utilizing a nonprocessive method but degrades
substrates at variable rates based on their structure. Our data
reveal for the first time that heparanase is an editing enzyme
that may regulate the release/preservation of specific saccha-
ride structures. This study advances our understanding of
heparanase recognition of HS and reveals an additional level of
HS regulation.
EXPERIMENTAL PROCEDURES
Expression of Heparanase Construct in Sf9 Cells—The
human single-chain GS3 construct for constitutively active
heparanase was constructed by removing the linker region
betweenGlu109 and Lys158 based on the report byNardella et al.
(15). In this construct, the 8- and 50-kDa subunits were linked
via three glycine-serine repeats with the nucleotide sequence
GGCTCGGGATCGGGTTCT to replace amino acid residues
from Glu109 to Lys158. The cDNA covering the GS3 construct
was synthesized by GenScript (Piscataway, NJ). The GS3 con-
struct was cloned into a pFastBac-Mel-HT vector using EcoRI
and NotI sites with primers 5-ATATTAGCGAATTCACAA-
GACGTGGTCGACCTCGAT-3 and 5-ATAAATGCGGC-
CGCATTAGATACAAGCGGCGACCTTAGCGTTACGGAT-
3, where the restriction sites of EcoRI and NotI are underlined
(16). Recombinant baculoviruses expressing heparanase GS3 (15)
were generated using the Bac-to-Bac baculovirus expression sys-
tem (Invitrogen). Recombinant baculoviruses were used to infect
Sf9 insect cells in shake cultures (2.0  106 cells/ml) grown in
Sf-900 III SFM (Invitrogen) at 27.5 °C and 135 rpm. After 72 h of
infection, the medium was centrifuged at 1000 rpm for 5 min to
pellet the cells, and the supernatant was collected. The superna-
tants were diluted 1:1 with buffer containing 50mMTris-HCl and
150mMNaCl (pH 7.5) and purified as outlined below.
Purification of Recombinant Heparanase—The recombinant
heparanase was purified using a similar method previously
described in U.S. Patent 2007/0009989 (17). Briefly, the diluted
supernatant was applied to a heparin HyperD column (Pall Life
Sciences) and washed with 50 mM Tris-HCl and 150 mM NaCl
(pH 7.5) at a flow rate of 2 ml/min. The protein was eluted with
50 mM Tris-HCl and 1.5 M NaCl (pH 7.5). Fractions containing
heparanase activity were pooled, mixed with glycerol at a final
concentration of 15%, and stored at 80 °C until used.
Preparation of Oligosaccharide Substrates—All oligosaccha-
rides were elongated from p-nitrophenyl (pNP) -glucuronide
(GlcUA-pNP), which was purchased from Sigma. The Penta-1
backbone with the structure GlcUA-N-trifluoroacetylgluco-
samine (GlcNTFA)-GlcUA-GlcNTFA-GlcUA-pNP was pre-
pared using a previously described method (13). Briefly,
GlcUA-pNPwas incubatedwith aUDP-monosaccharide donor
(UDP-GlcNAc, UDP-GlcNTFA, or UDP-GlcUA) and bacterial
glycosyltransferase (KfiA or Pasteurella multocida heparosan
synthase 2) in buffer containing 25 mM Tris-HCl (pH 7.2) and
10 mM MnCl2. To ensure that 95% of the UDP-monosaccha-
ride donor was converted to UDP, the reaction was incubated
for 16 h at room temperature and analyzed using a polyamine-
based HPLC column. After the addition of two monosaccha-
rides, the reaction was purified using a C18 column (0.75  20
cm; Biotage), whichwas elutedwith a linear gradient of 0–100%
acetonitrile in H2O and 0.1% TFA over 60 min at a flow rate of
2 ml/min. The product was determined by exploiting the UV
absorbance of the pNP tag at 310 nm, and the identity of the
product was confirmed by ESI-MS. The reaction cycle was
repeated two times to prepare the Penta-1 backbone. Further
elongation of Penta-1 to Hepta-2 and Nona-3 was achieved by
additional cycles with the incubation of UDP donors, KfiA, and
P. multocida heparosan synthase 2 following the same proce-
dure as described above. Alternatively, by alternating the addi-
tion of GlcNAc-GlcUA or GlcNTFA-GlcUA, we were able to
synthesize five additional nonasaccharides (Nona-4 to Nona-8)
by essentially the same protocol used above.
The N-sulfation of the oligosaccharide backbones was com-
pleted by detrifluoroacetylation, followed by N-sulfation with
N-sulfotransferase. The oligosaccharide backbones were dried
and resuspended (10 ml) in a solution containing CH3OH,
H2O, and (C2H5)3N (2:2:1, v/v/v). The reaction was incubated
at 37 °C for 16 h until detrifluoroacetylation reached comple-
tion. The detrifluoroacetylated substrates were dried, resus-
pended in H2O, and N-sulfated. In brief, N-sulfation was car-
ried out with N-sulfotransferase (67 g/ml) and 0.45 mM
3-phosphoadenosine 5-phosphosulfate in a total volume of 20
ml to yieldN-sulfated oligosaccharide substrates. 6-O-Sulfation
was carried out using 20 g/ml 6-O-sulfotransferase 1, 60
g/ml 6-O-sulfotransferase 3, and 0.45mM 3-phosphoadenos-
ine 5-phosphosulfate in buffer containing 50 mM MES. The
35S-labeled 6-O-sulfated products were synthesized utilizing
0.1 mg/ml 6-O-sulfotransferase 1, 0.3 mg/ml 6-O-sulfotrans-
ferase 3, and 50 M 3-phosphoadenosine 5-[35S]phosphosul-
fate in a 100-l reaction. The product purity and identity of the
synthesized oligosaccharides (Penta-1, Hepta-2, and Nona-3 to
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Nona-8) were confirmed by high resolution DEAE-HPLC and
ESI-MS, respectively.
Heparanase Enzymatic Reactions—Enzymatic reactionswith
35S-labeled material were carried out as described previously
(12). Enzymatic reactions with unlabeled material were carried
out under similar conditions with the following exceptions: 100
g/ml each substrate (Nona-3 and Nona-7) and 3.75 g/ml
heparanase. The reaction was incubated for 0, 5, 15, 25, 60, 120,
240, and 480min or 16 h at 37 °C, followed by subsequent heat-
ing (100 °C for 5min) and centrifugation (13,200 rpm for 5min)
to precipitate the insolublematerial. The reactionwas ready for
subsequent analysis.
High Resolution DEAE-HPLC Analysis—To elucidate the
cleavage dynamics of heparanase, recombinant heparanase was
incubated with 35S-labeled Nona-3 and Nona-7 at 0, 5, 15, 25,
60, 120, 240, and 480 min. The reaction was stopped by subse-
quent heating (100 °C for 5 min) and centrifugation (13,200
rpm for 5 min) to precipitate the insoluble material. The cleav-
age products were analyzed and separated on a DEAE-NPR
column (4.6 mm (inner diameter)  7.5 cm; Tosoh Biosci-
ences), which was eluted with a linear gradient 0–1 M NaCl in
20 mM Tris-HCl (pH 7.5) over 60 min at a flow rate of 0.4
ml/min.
Mass Spectrometry Analysis—MS analysis was performed on
a Thermo LCQDeca mass spectrometer. The oligosaccharides
were dissolved in H2O and injected via direct infusion (30
l/min) into the instrument. The experiments were performed
utilizing a negative ionizationmodewith a spray voltage of 3 kV
and a capillary temperature of 160 °C. The MS data were
acquired and processed using Xcalibur 1.3 software.
Separation of Oligosaccharide by Gel Permeation Chroma-
tography—The heparanase-digested products were separated
and purified by fractionation on a Bio-Gel P-2 column (0.75 
200 cm; Bio-Rad), which was equilibrated with a solution con-
taining 0.1 mM ammonium bicarbonate at a flow rate of 4 ml/h.
The identities of the cleavage products were confirmed as
described under “Mass Spectrometry Analysis.”
RESULTS
Preparation of Structurally Defined Oligosaccharide Sub-
strates—A library of oligosaccharides was synthesized to deter-
mine the specificity of heparanase. The library consisted of
eight oligosaccharides carrying 6-O-sulfo groups (Fig. 1). The
synthesis was completed using a chemoenzymatic approach
involving backbone elongation and sulfation steps. Elongation
was completed using two bacterial glycosyltransferases,
N-acetylglucosaminyltransferase from Escherichia coli strain
K5 (KfiA) (Fig. 1, Step a) andP. multocida heparosan synthase 2
(Fig. 1, Step b). In this synthesis, a GlcUA derivative (GlcUA-
pNP) was used as the starting material. The pNP group of the
starting material has absorbance at 310 nm, which facilitated
detection during analysis. The backbone oligosaccharides con-
tained strategically placed GlcNTFA residues, which were con-
verted toN-sulfoglucosamine (GlcNS) residues readily in a later
step (Fig. 1, Steps c and d) (13). This design allowed us to control
the positions of GlcNS residues in the oligosaccharides (Fig. 1,
Steps c and d). At the 6-O-sulfation step (Fig. 1, Step e), 6-O-
sulfotransferases 1 and 3were employed to fully 6-O-sulfate the
oligosaccharides. The structures of the substrates were con-
firmed by ESI-MS (Table 1 and supplemental Fig. S1). The 6-O-
[35S]sulfo-labeled substrates were also prepared and showed a
single symmetric peak in a high resolution DEAE-HPLC trace
(Table 1 and supplemental Fig. S2), suggesting that the purity of
the substrates was high. It is important to note that such struc-
turally diversified 6-O-sulfated nonasaccharide library had not
been synthesized previously.
Minimum Size for a Heparanase Substrate—We sought to
determine whether heparanase cleavage is dependent on the
FIGURE 1. Scheme for synthesis of oligosaccharide substrates. Synthesis was initiated from GlcUA-pNP. The starting monosaccharide was elongated by
glycosyltransferases to the desired size. The resultant oligosaccharides were then N-sulfated and 6-O-sulfated by N-sulfotransferase (NST) and 6-O-sulfotrans-
ferases 1 and 3 (6OSTs), respectively. A total of eight oligosaccharides were synthesized, and structural analysis of each oligosaccharide was conducted by
ESI-MS (supplemental Fig. S1). The purity was assessed by DEAE-HPLC (supplemental Fig. S2). KfiA is the N-acetylglucosaminyltransferase from E. coli strain K5.
pmHS2, P. multocida heparosan synthase 2; GlcA, GlcUA; PAPS, 3-phosphoadenosine 5-phosphosulfate.
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size of the substrate. To this end, we employed three oligosac-
charides (Penta-1, Hepta-2, and Nona-3) that contained differ-
ent numbers of GlcUA-GlcNS6S repeating units: Penta-1,
Hepta-2, and Nona-3 have two, three, and four repeats of the
unit, respectively. Subjecting 35S-labeledNona-3 to heparanase
digestion yielded three products asmeasured by gel permeation
chromatography (Bio-Gel P-2), suggesting that two glycosidic
bonds were susceptible to the digestion (Fig. 2A). Structural
analysis of heparanase-digestedNona-3 was carried out by ESI-
MS. In this experiment, unlabeled Nona-3 was first digested
with heparanase, and the products were resolved using a Bio-
Gel P-2 column. The fractions from the Bio-Gel P-2 column
were subjected to ESI-MS analysis. An oligosaccharide with a
molecularmass of 1013.0 0.4 Dawas identified in fraction 42,
which is very close to the calculated molecular mass of 1012.8
Da for a tetrasaccharide with the structure GlcNS6S-GlcUA-
GlcNS6S-GlcUA (Tetra-17) (Fig. 2B and supplemental Table
1). The data suggest that this tetrasaccharidewas from themiddle
segment (residues4–7)ofNona-3 (Fig. 2).Usinga similarmethod,
a trisaccharide with the structure GlcUA-GlcNS6S-GlcUA (Tri-
12) and a pNP-tagged disaccharide with the structure GlcNS6S-
GlcUA-pNP (Di(pNP)-9) were identified (Fig. 2B and supplemen-
tal Table 1). These data allowed us to determine the sites of
heparanase cleavage of Nona-3 as depicted in Fig. 2C.
Digestion of 35S-labeled Hepta-2 with heparanase yielded
two 35S-labeled products, suggesting that the substrate con-
tained a single cleavage site (Table 1 and supplemental Fig. 3A).
Unlike Nona-3, 15% of Hepta-2 remained undigested, sug-
gesting that the susceptibility of the substrate to the digestion of
heparanase was size-dependent. The structures of those two
products were identified to be a trisaccharide (Tri-12) with a
molecular mass of 691.6  0.5 Da, which is close to the calcu-
lated molecular mass of GlcUA-GlcNS6S-GlcUA (691.6 Da),
and a tetrasaccharide (Tetra(pNP)-14)with amolecularmass of
1134.0 0.4Da,which is close to the calculatedmolecularmass
of GlcNS6S-GlcUA-GlcNS6S-GlcUA-pNP (1133.9 Da) (Table
1 and supplemental Fig. 3B). Interestingly, subjecting Penta-1
to heparanase digestion resulted in partial digestion, as 71% of
the starting material remained (supplemental Fig. S4), further
strengthening the conclusion that the susceptibility to hepara-
nase cleavage is dependent on the size of the substrate.
The results from the structural analysis of the cleavage prod-
ucts suggest that heparanase cleaves only the internal glycosidic
linkages. For example, when Nona-3 was used as a substrate,
heparanase did not cleave the bond between residues 1 and 2,
representing an exoglycosidic bond. A similar phenomenon
was observed for shorter substrates: Hepta-2 and Penta-1. Our
result is consistent with the conclusion that heparanase is an
endolytic hydrolase (11, 18). The substrates employed here
have the linkage GlcUA-GlcNS6S, which could have been
susceptible to heparanase digestion if it contains exolytic
activity. Heparanase showed a preference for cleavage of the
endoglycosidic bonds. Thus, our results provide direct evi-
dence that heparanase exclusively displays endolytic glucu-
ronidase activity.
Role of GlcNS6S/GlcNAc6S in Directing Heparanase
Cleavages—The disaccharide repeating units GlcUA-GlcNS6S
and GlcUA-GlcNAc6S co-exist throughout HS in low sulfated
TABLE 1
Summary of heparanase cleavages of oligosaccharide substrates
1 The oligosaccharides were prepared by chemoenzymatic synthesis.
2 The arrows indicate the sites of heparanase cleavage.
3 The molecular masses were determined by ESI-MS.
4 Percent purity was calculated using high resolution DEAE-HPLC.
Substrate Specificity of Heparanase
OCTOBER 5, 2012 • VOLUME 287 • NUMBER 41 JOURNAL OF BIOLOGICAL CHEMISTRY 34839
domains. Although heparanase is known to cleave the -GlcUA-
GlcNS6S- linkage, the effect of a nearby disaccharide unit of
-GlcUA-GlcNAc6S- on the action of heparanase has not been
investigated. Here, we prepared a series of nonasaccharide sub-
strates that contained the mixing disaccharide units GlcUA-
GlcNAc6S and GlcUA-GlcNS6S. GlcUA-GlcNAc6S can be
located at the nonreducing end (Nona-4 and Nona-5), the
reducing end (Nona-6), and both ends (Nona-7) and alternated
with GlcUA-GlcNS6S units (Nona-8). These substrates pro-
vided us the opportunity to systematically examine the contri-
bution of the GlcNAc6S motif to the selection of cleavage sites
by heparanase. The 35S-labeled and unlabeled substrates were
treated with heparanase and analyzed using a Bio-Gel P-2 col-
umn and by ESI-MS (Table 1 and supplemental Figs. S5–S9).
All of these substrates, with the exception of Nona-8, were
completely digested by heparanase.
Carefully examination of the structures of the digestion
products from six nonasaccharide substrates revealed that
the heparanase cleavage sites depend on the substrate saccha-
ride sequences (Fig. 3). Two groups were observed: consecutive
cleavage and gapped cleavage. In the consecutive cleavage
group, heparanase cleaved the glycosidic bond between resi-
dues 3 and 4 as well as the one between residues 5 and 6,
whereas the bond between residues 7 and 8 remained intact,
resulting in a trisaccharide, a disaccharide, and a pNP-tagged
tetrasaccharide product. Four nonasaccharide substrates
(Nona-4, -5, -7, and -8) displayed the consecutive cleavage
pattern (Fig. 3A and Table 1). In the gapped cleavage group,
heparanase cleaved the glycosidic bond between residues 3 and
4 and the one between residues 7 and 8, whereas the linkage of
residues 5 and 6 was untouched, resulting in a trisaccharide, a
tetrasaccharide, and a pNP-tagged disaccharide. Two nonasac-
charides (Nona-3 and Nona-6) displayed the gapped cleavage
pattern (Fig. 3B andTable 1). The notable structural differences
among these nonasaccharides are located at the nonreducing
end. In Nona-4, -5, -7, and -8 (consecutive cleavage group),
GlcNAc6S is present at residue 2, whereas this residue is
replaced with GlcNS6S in Nona-3 and Nona-6 (gapped cleav-
age group). Our data suggest that heparanase is capable of rec-
ognizing GlcNS6S and GlcNAc6S residues on the nonreducing
side, which determines the cleavage susceptibility of the
remaining sites.
Heparanase Cleavage Site Preference—To establish the
cleavage site preference, we performed a time course analysis of
the enzyme-catalyzed reaction using Nona-3 (N-sulfation at
the nonreducing end) and Nona-7 (N-acetylation at the nonre-
ducing and reducing ends). First, we compared the digestion
time courses for Nona-3 and Nona-7 using 35S-labeled sub-
strates, followed by DEAE-HPLC analysis. For the 35S-labeled
Nona-3 substrate, different 35S-labeled peaks emerged as the
digestion proceeded (Fig. 4A). In the mean time, a decrease in
the intensity of Nona-3 (eluted at 47 min) was observed. For
example, two 35S-labeled peaks, which were eluted at 16 and 42
min from the DEAE-HPLC column, were observed when hepa-
ranase and the substrate were incubated for 25 min. As the
incubation time was extended, the intensity of the 35S-labeled
peak that eluted at 42 min decreased, and an additional 35S-
labeled peaked emerged at 14 min (Fig. 4A). Very similar
profiles were obtained when Nona-7 was incubated with
heparanase at similar time intervals (Fig. 4B). These data
FIGURE 2. Analysis of heparanase-digested Nona-3. A, Bio-Gel P-2 elution profiles of 35S-labeled Nona-3 without (upper panel) and with (lower panel)
heparanase digestion. B, ESI-MS spectra of heparanase-digested Nona-3 from fractions eluted from the P-2 column. Left panel, spectrum of Tri-12 from fractions
51–57. Middle panel, spectrum of Tetra-17 from fractions 43– 49. Right panel, spectrum of Di(pNP)-9 from fractions 71–75. C, chemical reaction involved in the
digestion of Nona-3 with heparanase.
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suggest that intermediate oligosaccharides were formed dur-
ing the digestion.
Second, we sought to determine the structures of the inter-
mediates that resulted from partial digestions of unlabeled
Nona-3 and Nona-7 by heparanase. For Nona-3, the digestion
was stopped at 30 min, and the products were analyzed by
ESI-MS (supplemental Fig. S10). Two products were identified:
Tri-12 andHexa(pNP)-18.Our results indicate that heparanase
cleaves the glycosidic bond of Nona-3 that is located closer to
the nonreducing end. For Nona-7, the digestion with hepara-
nase was also stopped at 30 min, and the products were sub-
jected to ESI-MS analysis (supplemental Fig. S11). Two oligo-
saccharides were identified: Tri-13 and Hexa(pNP)-19. Hence,
our data suggest that heparanase cleaves the glycosidic bond
closer to the nonreducing end to release a trisaccharide and a
hexasaccharide. The resultant hexasaccharide was subse-
quently digested to the final products. Although the digestion
of both Nona-3 and Nona-7 followed a similar degradation
pathway, the initial rate of the first digestion step from nonasa-
ccharide to hexasaccharide was significantly different. A signif-
icant portion of Nona-3 remained after 25 min of digestion,
whereas only 15–20% of Nona-7 was present. On the other
hand, in the later digestion step fromhexasaccharide to tetrasa-
ccharide, Hexa(pNP)-18 fromNona-3 disappearedmuch faster
than Hexa(pNP)-19 from Nona-7.
The results from the time course study also suggest that
heparanase cleaves distributively during the digestion of the
segment with a repeating disaccharide unit of -GlcUA-GlcNS-
(orGlcNAc)6S-. In a distributive reaction, it is assumed that the
substrate has to associate with the enzyme multiple times to
undergo complete degradation. Therefore, the starting mate-
rial and intermediatemust compete for binding to the substrate
to undergo degradation in a distributive reaction (19). This
competition can be observed in the time course study (Fig. 4). In
the heparanase degradation reactions, the nonasaccharide
starting material has to compete with the trisaccharide and
hexasaccharide for binding to heparanase to undergo further
degradation. As a result of heparanase cleavage size depend-
ence, the intermediate in both reactions cannot be degraded
into the final product until all of the startingmaterial is cleaved.
DISCUSSION
Heparanase is reportedly involved in a wide range of patho-
physiological functions, including stimulating tumor metasta-
sis, inflammatory responses, and autoimmune-mediated cell
damage (20–22). These diversified functions of heparanase are
attributed predominantly to the release of short HS fragments
from the action of heparanase on HS present in the extracellu-
larmatrix. The degradedHS fragments bind to different growth
factors and chemokines that regulate a series of cellular events.
Therefore, understanding the substrate specificity of hepara-
nase is essential for deciphering the roles of heparanase in reg-
ulating or stimulating diseases at the molecular levels.
In this study, we employed a selective library of oligosaccha-
rides coupled with ESI-MS analysis to determine the substrate
specificity of heparanase. AlthoughHS has complex saccharide
sequences, we focused only on substrates containing the
disaccharide repeating units -GlcUA-GlcNS6S- and -GlcUA-
GlcNAc6S-. This selection was based on the fact that -GlcUA-
GlcNS6S- is known to be the site cleaved by heparanase (6, 11,
12). The structural domain of -IdoUA2S-GlcNS6S- was not
included in this study because this repeating unit is resistant to
heparanase digestion (11, 12). We also chose to synthesize
oligosaccharides containing the disaccharide unit -GlcUA-
GlcNAc6S-, permitting us to examine the effects of the
GlcNAc6S residue on substrate specificity. Collectively, the uti-
lization of these substrates provided the opportunity to exam-
ine the substrate specificity of heparanase in greater detail.
We discovered that heparanase cleaves both the -GlcUA-
GlcNAc6S and -GlcUA-GlcNS6S- linkages. The susceptibility
of the -GlcUA-GlcNAc6S- linkage to heparanase cleavage is
somewhat surprising, as it was concluded to be resistant to
heparanase cleavage using a synthetic polysaccharide substrate
that contains the linkage -GlcUA-GlcNAc- or -GlcUA-
FIGURE 3. Schematic representation of heparanase cleavage of different nonasaccharide substrates. A, consecutive cleavage pattern. When GlcNAc6S is
present at residue 2, heparanase displays the consecutive cleavage pattern, namely cleaving the linkages between residues 3 and 4 and residues 5 and 6.
B, gapped cleavage pattern. When GlcNS6S is present at residue 2, heparanase displays the gapped cleavage pattern, namely cleaving the linkages between
residues 3 and 4 and residues 7 and 8 and skipping the bond between residues 5 and 6. GlcA, GlcUA.
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GlcNAc6S- (but not -GlcUA-GlcNS6S-) (12). The discrepancy
is likely due to the fact that the presence of -GlcUA-GlcNS6S-
renders heparanase susceptible to the -GlcUA-GlcNAc6S-
linkage. The sulfated saccharide sequence that influences sus-
ceptibility to heparanase cleavage has been found (12). For
example, the -GlcUA-GlcNS- linkage is resistant to heparanase
digestion; however, this linkage can be susceptible to hepara-
nase cleavage when a 2-O-sulfated GlcUA residue is located
nearby (12).
Our data indicate that heparanase is able to degrade the sub-
strates in twomodes: consecutive cleavage and gapped cleavage
(Fig. 4). In the consecutive cleavage mode, heparanase removes
three saccharide residues from the nonreducing end and then
by removes two additional residues from the nonreducing end.
FIGURE 4. DEAE-HPLC chromatograms of 35S-labeled Nona-3 and Nona-7 digested with heparanase at different times. Heparanase was incubated with
35S-labeled Nona-3 and Nona-7 at 0, 5, 15, 25, 60, 120, 240, and 480 min. The reaction was stopped, and the cleavage products were analyzed and separated by
high resolution DEAE-HPLC. A, degradation of 35S-labeled Nona-3 and Nona-7 at 0 – 480 min by heparanase. B, upper panel, schematic identifying the cleavage
products from the chemical reaction involved in the digestion of Nona-3 with heparanase. Lower panel, chemical reaction involved in the digestion of Nona-7
with heparanase. GlcA, GlcUA.
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In the gapped cleavage mode, heparanase also removes the
three saccharide residues from the nonreducing end and skips
the immediate next cleavage site, leaving a bigger fragment
from the internal portion of the substrate. Heparanase displays
the consecutive cleavagemode when a GlcNAc6S residue is pres-
ent in the nonreducing end trisaccharide domain, whereas it dis-
plays the gapped cleavage mode when the GlcNAc6S residue is
replaced with a GlcNS6S residue. Several mechanisms are possi-
ble. For example, heparanase has two distinct active sites. One site
is responsible for the consecutive cleavage mode and prefers to
accommodate the substrate with GlcNAc6S at the nonreducing
end. Another site is responsible for the gapped cleavagemode and
recognizes the substrate with GlcNS6S at the nonreducing end.
However, only one active site has been identified based on the
homology model (23). Alternatively, the trisaccharide domain
from the nonreducing end serves as amodulator to direct hepara-
nase to display the consecutive or gapped cleavagemode. Because
our data show that heparanase releases the nonreducing end tri-
saccharide first before it further degrades the substrate, the latter
mechanismwarrants further investigation.
Our discovery of the distinct heparanase cleavage modes
provides insights into the role of heparanase in controlling/
preserving the functions of HS. HS consists of highly sulfated as
well as low sulfated domains (2). Heparanase is believed to serve
as an editing enzyme to excise HS to release those fragments
with high potency to stimulate the actions of growth factors/
growth factor receptors and chemokines/chemokine receptors
(20). The highly sulfated domain, also known as the S-domain,
contributes to the binding to growth factors and chemokines.
This domain contains the disaccharide repeating units
-IdoUA2S-GlcNS6S- and -GlcUA-GlcNS6S- (24). Although
the IdoUA2S-GlcNS6S linkage is known to be resistant to
heparanase action, the reason for the lack of cleavage of the
GlcUA-GlcNS6S linkage in the S-domain is less clear. The dis-
covery of the “gapped” cleavage mode could potentially con-
tribute to preserve the integrity of the S-domain, especially
playing a role in reducing cleavage of the -GlcUA-GlcNS6S-
linkage. At this time, the precise link between different cleavage
modes and the regulation of HS degradation remains elusive.
Nevertheless, these results should advance the understanding
of the regulation of HS biosynthesis and the intimate relation-
ship between HS and heparanase. Further investigation on the
mechanism that directs heparanase cleavage will aid in deci-
phering the wide range of pathophysiological functions of
heparanase in vivo.
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